Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 5/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP8 | P22894 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7240622 | 0.88 | LMNA (0.53) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL7221503 | 0.84 | LMNA (0.54) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL7229882 | 0.83 | GAA (0.50) | LMNA | |
| SCHEMBL7228473 | 0.83 | MAPT (0.40) | CA1CA9CA2CA12LMNA | |
| SCHEMBL8415189 | 0.80 | CA1 (0.62) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL7223994 | 0.78 | POLB (0.36) | LMNA | |
| SCHEMBL1201738 | 0.77 | AKR1B1 (0.60) | CA1CA9CA2CA12LMNA | |
| SCHEMBL7223364 | 0.77 | POLB (0.45) | — | |
| SCHEMBL7225299 | 0.77 | ALDH1A1 (0.43) | LMNA | |
| SCHEMBL8467038 | 0.76 | ALDH1A1 (0.52) | CA1CA9CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | disclosed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | disclosed |
| EP-0946503-B1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 2002-03-27 | — | — | EP | disclosed |
| EP-0946503-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GmbH (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028265-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | AKR1B1, ALDOA, AKR1C1 | MMP1 434/4885MMP2 1461/4885MMP9 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.